NASDAQ:GNCAQ Genocea Biosciences (GNCAQ) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitors About Genocea Biosciences Stock (NASDAQ:GNCAQ) Get Genocea Biosciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume1,863 shsMarket Capitalization$5 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genocea Biosciences, Inc. was a biotechnology company focused on developing immunotherapies and vaccines designed to activate disease-specific T-cell responses. The company used its proprietary ATLAS platform to identify antigens recognized by T cells and support the development of treatments for infectious diseases and cancer. Its historical pipeline included GEN-003, a therapeutic vaccine candidate for genital herpes caused by herpes simplex virus type 2, and GEN-009, a personalized neoantigen vaccine intended to stimulate immune responses against cancer. Genocea also evaluated additional immuno-oncology programs based on its antigen-discovery technology. Founded in 2006 and headquartered in Cambridge, Massachusetts, Genocea conducted clinical and development activities primarily in the United States. Chip Clark served as the company’s president and chief executive officer during a significant portion of its development. Genocea later discontinued operations and entered bankruptcy proceedings, and its former Nasdaq security trades under the GNCAQ symbol.AI Generated. May Contain Errors. Read More Receive GNCAQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNCAQ Stock News HeadlinesMicrobix Biosystems Inc. (MBXBF)July 25, 2024 | finance.yahoo.comGenocea Bio (GNCAQ) Earnings Dates & ReportsAugust 19, 2023 | investing.comAI Panic: Sell now or wait?Bank of America, Goldman Sachs, and Morgan Stanley have reportedly warned private clients about a coming stock market crisis. Business Insider says it could mean a brutal decade ahead for stocks, one that could keep portfolios in the red well into the 2030s. New technology may offer a way to prepare before the warning plays out.September 24 at 1:00 AM | TradeSmith (Ad)Genocea Biosciences Inc (GNCAQ)August 11, 2023 | uk.investing.comGNCAQ - Genocea Biosciences, Inc.June 1, 2023 | ca.finance.yahoo.comSee More Headlines GNCAQ Stock Analysis - Frequently Asked Questions How do I buy shares of Genocea Biosciences? Shares of GNCAQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:GNCAQ CIK1457612 Webwww.genocea.com Phone(617) 876-8191Fax617-876-8192Employees70Year Founded2006Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares53,020,000Free FloatN/AMarket Cap$5 thousand OptionableNot Optionable Beta2.44 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:GNCAQ) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNCAQ Stock Alerts